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Abstract Although both ceramide and interleukin-ll] convert- apoptosis [15-18]. However, ICE itself might not be a true 
mammalian Ced-3 counterpart because apoptosis proceeds al- ing enzyme (ICE) family proteases are key molecules during 
apoptosis, their relationship remains to be elucidated. We report most normally in ICE-deficient mice [19,20]. So far at least 
here that cell-permeable ceramide induced cleavage and activa- seven mammalian Ced-3 homologues have been identified, 
tion of CPP32, a Ced-3/ICE-like protease, but not ICE. and all of them are aspartate-directed cysteine proteases cap- 
Ceramide-induced apoptosis of Jurkat cells was blocked by the able of inducing apoptosis [21]. Among them, CPP32 (apo- 
CPP32-specific tetrapeptide inhibitor DEVD-CHO, but not by pain [22], Yama [23]) appears to be a real mammalian Ced-3 
the ICE inhibitor YVAD-CHO. Furthermore, variant Jurkat counterpart, because it has greater homology (35% identity) 
cells with defective CPP32 activation were resistant o both anti- with Ced-3 than ICE [24], and has been identified as the en- 
Fas- and ceramide-induced apoptosis. These results indicate that zyme that cleaves poly-ADP ribose polymerase (PARP) which 
CPP32 activation is required for ceramide-induced apoptosis, 
and suggest sphingomyelin-ceramide pathway functions upstream appears to be involved in DNA repair and the maintenance of 
of CPP32. genome integrity [22,23]. More recently, CPP32 was shown to 
be the key ICE-like protease in Fas-mediated apoptosis [25]. 
Key words." CPP32; Ceramide; Apoptosis; Fas; Interleukin- Although numerous reports have established the role of 
113 converting enzyme ceramide and ICE-like proteases in apoptosis, it has not yet 
been established whether they work independently in separate 
signal transduction pathways, or one acts upstream of and 
requires the other. In TNF-induced apoptosis, both ceramide 
1. Introduction generation [9,10,26] and ICE-like protease activation [17] re- 
quire TNFRI(p55), especially the death domain, but not 
Apoptosis is a well-regulated process of cell death that is TNFRII(p75), raising the possibility that ceramide and ICE- 
important in events such as embryogenesis, cell growth con- like proteases exist in the same signaling pathway. We there- 
trol and lymphocyte repertoire formation. Recent investiga- fore addressed this question in the present study and demon- 
tions have revealed that there are several key pathways in strated that CPP32 acts downstream of ceramide and its acti- 
apoptotic signal transduction, including the sphingomyelin- vation is required for ceramide-induced apoptosis. 
ceramide pathway [1,2] and the pathway involving interleu- 
kin-l~ converting enzyme (ICE)/Ced-3 family proteases [3]. 2. Materials and methods 
Ceramide is a newly identified lipid second messenger that 
is generated through the hydrolysis of sphingomyelin by 2.1. Reagents and cell lines 
sphingomyelinases (SMase) [1,2]. Signals from cell surface re- N-Acetyl ceramide (C2-ceramide) was purchased from Wako (Osa- 
ceptors such as Fas (CD95/Apol) [4-7] and tumor necrosis ka), C2-dihydroceramide from Calbiochem and dioctanoylglycerol 
factor receptor (TNFR) [8-11] activate SMase and generate from Sigma, and dissolved in ethanol. The final ethanol concentration 
in the culture medium was always less than 0.1%. Mouse IgM anti- 
ceramide, even in the cell-free system [12]. Synthetic cell- human Fas monoclonal ntibody (CH-11) was purchased from Med- 
permeable ceramide can mimic such apoptosis. This cytotoxic ical Biological Laboratories (Nagoya) and anti-CPP32 monoclonal 
effect is specific because structural analogues such as dihydro- antibody from Transduction Laboratories. Tetrapeptide inhibitors 
ceramide do not induce apoptosis [13,14]. These data suggest for CPP32 (Ac-DEVD-CHO) and ICE (Ac-YVAD-CHO), and tetra- 
that ceramide is a physiological mediator of Fas- and TNFR- peptide substrates for CPP32 (Ac-DEVD-AMC) and ICE (Ac- 
YVAD-AMC) [22,27] were purchased from Peptide Industries (Osa- 
mediated apoptosis, ka) and dissolved in DMSO. The human T cell line, Jurkat, was 
ICE family proteases, which are mammalian Ced-3 homo- maintained in RPMI 1640 medium containing 10% fetal calf serum 
logues, have also been implicated in Fas- and TNF-mediated (FCS). An anti-Fas-resistant (FR) subline of Jurkat was established 
by culturing wild-type Jurkat cells in the presence of 100 ng/ml anti- 
Fas (CH-11) for 1 month. 
*Corresponding author. Fax: (81) (3) 5803-0131. 
2.2. Immunoblotting of CPP32 
**Research fellow of the Japan Society for the Promotion of Science. Jurkat cells (1 × 106) were treated with 10 gM C2-ceramide in
RPMI 1640 medium containing 1% FCS for the indicated time peri- 
Abbreviations." ICE, interleukin-l[~ converting enzyme; SMase, sphin- ods. Cell pellets were lysed in lysis buffer containing 125 mM Tris- 
gomyelinase; TNFR, tumor necrosis factor receptor; PARP, poly- HC1 pH 6.8, 2% SDS, 5% glycerol, and 1% [~-mercaptoethanol, d 
ADP ribose polymerase; FCS, fetal calf serum; AMC, 7-amino-4- boiled for 5 min. The samples were separated on 15% SDS-polyacryl- 
methyl-coumarin amide gel, electrotransferred to a polyvinylidene difluoride membrane, 
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immunoblotted with anti-CPP32 p17 monoclonal ntibody, and devel- 
oped by an enhanced chemiluminescence (ECL) system (Amersham). 0 1 5 30  60  90  ( ra in )  
2.3. Measurement of protease activity ~ " - -  . . . . . . . . . . . . . . .  p32  
Cells (7 × l05) were lysed with 300 lal of 0.5% Nonidet P-40, 0.5 mM 
EDTA, 150 mM NaC1, and 50 mM Tris pHT.5. Aliquots (50 pJ) of the 
extracts were incubated with 40 p.M tetrapeptide substrate, l0 mM 
HEPES, pH7.5, 0.05 M NaC1, and 2.5 mM DTT in 200 lal of reaction 
mixture for 2 h at 37°C. The fluorescence of released 7-amino-4- 
methyl-coumarin (AMC) was measured using an excitation wave 
length of 365 nm and emission wave length of 450 nm. 
2.4. Assessment of apoptosis 
Jurkat cells, with or without preincubation with tetrapeptide inhib . . . . . .  
itors for 3 h, were treated with anti-Fas antibody (200 ng/ml) or C2- "~"~ ~ p 1 7 
ceramide (10 ~M) in RPMI 1640 medium containing 1% FCS. At the 
indicated time points, the cells were harvested and fixed with 1% 
glutaraldehyde in PBS. After washing with PBS, cells were stained Fig. 1. Cleavage of CPP32 during ceramide-induced apoptosis. The 
with 0.2 mM Hoechst 33258 and examined by fluorescence micro- extracts from ceramide-treated cells were subjected to immunoblot 
scopy. Nuclei were scored as apoptotic if they exhibited condensation analysis using anti-CPP32 pl7 antibody. The active subunit (pl7) 
or fragmentation f chromatin. A minimum of 250 cells were counted was generated by the cleavage of p32 pro-enzyme in a time-depen- 
for quantitation. Cell viability was measured by the WST-1 tetrazo- dent fashion. 
lium assay (Dojindo, Kumamoto) [28,29]. 
3. Results anti discussion cific to CPP32 [22], was detected as early as 2 h after the 
addition of ceramide and increased thereafter (Fig. 2). On 
In order to examine whether exogenous ceramide induces the other hand, we detected no cleavage after YVAD, which 
either CPP32 or ICE activation, we cultured Jurkat cells with is specific to ICE activity, during ceramide-induced apoptosis 
cell-permeable C2-ceramide. C2-ceramide induced typical (Fig. 2). As recently reported by Schlegel et al. [25], the activ- 
morphological changes een in apoptosis, such as membrane ity of CPP32 but not ICE was increased uring Fas-mediated 
blebbing, nuclear condensation and fragmentation, and in- apoptosis. Its kinetics was similar to that of ceramide-induced 
creased numbers of hypodiploid nuclei (not shown). CPP32 apoptosis (Fig. 2). Taken together, the data suggest that 
is a cysteine protease known to be activated by proteolytic CPP32 but not ICE is activated in both ceramide and Fas- 
cleavage, p32 precursor was cleaved at two aspartate residues, mediated apoptosis of Jurkat cells. 
thus creating two subunits, p17 and pl2 [22]. We assessed The effect of ceramide to induce apoptosis is specific be- 
whether this cleavage occurs during ceramide-induced apop- cause dihydroceramide, which is a structural analogue of cer- 
tosis by immunoblotting with anti-pl7 antibody. Following amide, does not induce apoptosis [13,14]. We examined the 
the addition of ceramide, the 32 kDa pro-enzyme was cleaved, ability of cell-permeable lipids to induce CPP32 activation in 
and the 17 kDa subunit was generated in a time dependent Jurkat cells. CPP32 activity induced by C2-dihydroceramide 
manner (Fig. 1). These results indicated that the proper pro- was minimal (Fig. 3), and apoptotic morphological changes 
teolytic processing of CPP32 occurred during ceramide-in- were not observed. Dioctanoylglycerol (cell-permeable diacyl- 
duced apoptosis, and suggested that CPP32 was activated, glycerol) had no effect. The results suggested that the action 
No ICE p45 pro-enzyme was detected in the lysate of Jurkat of ceramide is specific for some target molecules, rather than 
cells (not shown), nonspecific ytotoxic or membrane-toxic effects by cell perme- 
To confirm the CPP32 activation during ceramide-induced able lipids. 
apoptosis, cytosolic extracts from the ceramide-treated Jurkat To assess whether CPP32 activation is the essential event in 
cells were subjected to protease activity assay using tetrapep- ceramide-induced apoptosis, we determined whether cera- 
tide substrate. Enzymatic leavage after DEVD which is spe- mide-induced apoptosis is blocked by CPP32 inhibitor. 
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Fig. 2. CPP32 activation induced by ceramide and anti-Fas antibody. Jurkat cells were treated with C2-ceramide (10 p.M) or anti-Fas antibody 
(CH-11, 200 ng/ml) for various incubation periods. Cytoplasmic extracts were examined for protease activity. CPP32 and ICE enzyme activity 
is expressed as AMC release from the fluorogenic substrates Ac-DEVD-AMC (squares) and Ac-YVAD-AMC (circles), respectively. Data are 
representative of three experiments. 
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6" CPP32 specific inhibitor, the tetrapeptide aldehyde Ac- 
• DEVD-CHO or ICE-specific inhibitor, Ac-YVAD-CHO 
5"  [22,27] was added 3 h before ceramide treatment. As shown 
• in Fig. 4A,B, Ac-DEVD-CHO blocked the ceramide-induced 
E 4"  apoptosis in a dose-dependent manner. It also inhibited cell 
morphological changes uch as membrane blebbing. In con- 
0) to 3 trast, the ICE inhibitor did not block apoptosis even at a high 
t~ concentration (Fig. 4A,B). Similarly, Fas-mediated apoptosis i1) 
2 was also specifically blocked by the CPP32 inhibitor (Fig. 4B). 
O ~ These results suggested that activation of CPP32, not ICE, is 
~; ~ required for both ceramide- and anti-Fas-induced apoptosis. 
< 1 To further confirm that CPP32 activation is required for 
0 ceramide-induced apoptosis, a variant Jurkat cell subline re- 
sistant o anti-Fas antibody treatment (Jurkat FR) was stud- 
--~o (.9~ O~ ~a ied. It was established by culturing Jurkat cells with 100 ng/ml 
r- ~ ~ of CH-11 Although Jurkat FR express the same level of o (.9 
o O, cell surface Fas antigen as wild-type Jurkat (not shown), it 
was resistant o high doses of CH-11 (Fig. 5A). In this var- 
>- iant, activity of CPP32 after anti-Fas treatment was sup- 
:5 pressed (Fig. 5B). Whereas both cell lines expressed a similar 
level of CPP32 pro-enzyme, cleavage of p32 in Jurkat FR was Fig. 3. CPP32 activation induced by cell permeable lipids. Jurkat 
cells were treated with vehicle alone, 10 gM of C2-ceramide, 10 gM delayed (not shown). Since the CPP32 inhibitor blocked Fas- 
of C2-dihydroceramide or 10 M of DAG (dioctanoylglycerol) for mediated apoptosis of Jurkat cells (Fig. 4B), inefficient CPP32 
4 h. CPP32 activity was examined as in Fig. 2. The results are ex- activation appears to be responsible for anti-Fas resistance in 
pressed as means + S.D. of three independent experiments. Jurkat FR. We therefore xamined the sensitivity of this sub- 
line to ceramide-induced apoptosis, in order to confirm that it 
requires CPP32 activation. The results showed Jurkat FR was 
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Fig. 4. Specific inhibition of ceramide-induced apoptosis by CPP32 inhibitor. A: Jurkat cells were preincubated with 50 gM CPP32 inhibitor 
(Ac-DEVD-CHO) (c), 100 gM ICE inhibitor (Ac-YVAD-CHO) (d) or DMSO alone (a,b) for 3 h, then treated with (b d) or without (a) 10 
gM C2-ceramide for an additional 5 h. Cells were fixed with 1% glutaraldehyde and stained with Hoechst 33258. B: Cells were incubated with 
various doses of CPP32 inhibitor before C2-ceramide or anti-Fas antibody (CH-11) treatment. The percentage of apoptotic ells was determined 
by examining at least 250 cells. 
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Fig. 5. Resistance to ceramide-induced apoptosis of Jurkat cells with defective CPP32 activation. A,C: Wild-type Jurkat cells (open squares) 
and anti-Fas-resistant Jurkat cells (Jurkat FR, filled squares) were treated with either CH-11 (A) or C2-ceramide (C) for 5 h. Cell viability was 
examined by WST-1 tetrazolium assay. B,D: CPP32 enzyme activity of wild-type Jurkat (open squares) and Jurkat FR (filled squares) in re- 
sponse to 200 ng/ml CH-11 (B) and 10 gM C2-ceramide (D). 
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